Changchun High-tech: Subsidiary GenSci141's domestic production drug registration clinical trial application has been accepted

Changchun High-tech announced that its subsidiary Jinsai Pharmaceutical has received the "Acceptance Notification" issued by the National Medical Products Administration for the registration clinical trial application of its GenSci141 ointment. This drug is a testosterone ointment, classified as chemical drugs 2.2 and 2.4, used to improve small penis in children. If the clinical trial progresses smoothly, it will benefit the company in expanding its business and optimizing its product structure. However, medical product research and development have long cycles and multiple stages, and there is uncertainty in the progress of clinical trials.